ES2258453T3 - Metodo para identificar un individuo con riesgo de daños neurologicos irreversibles, que comprende las etapas de determinacion cuantitativa de la concentracion de pepsinogeno (i) y vitamina b12. - Google Patents

Metodo para identificar un individuo con riesgo de daños neurologicos irreversibles, que comprende las etapas de determinacion cuantitativa de la concentracion de pepsinogeno (i) y vitamina b12.

Info

Publication number
ES2258453T3
ES2258453T3 ES00922683T ES00922683T ES2258453T3 ES 2258453 T3 ES2258453 T3 ES 2258453T3 ES 00922683 T ES00922683 T ES 00922683T ES 00922683 T ES00922683 T ES 00922683T ES 2258453 T3 ES2258453 T3 ES 2258453T3
Authority
ES
Spain
Prior art keywords
concentration
vitamin
analyte
individual
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00922683T
Other languages
English (en)
Spanish (es)
Inventor
Pentti Sipponen
Matti Harkonen
Osmo Suovaniemi
Erik Forsblom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohit Oy
Original Assignee
Biohit Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oy filed Critical Biohit Oy
Application granted granted Critical
Publication of ES2258453T3 publication Critical patent/ES2258453T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
ES00922683T 1999-04-30 2000-04-28 Metodo para identificar un individuo con riesgo de daños neurologicos irreversibles, que comprende las etapas de determinacion cuantitativa de la concentracion de pepsinogeno (i) y vitamina b12. Expired - Lifetime ES2258453T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI990991A FI990991L (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi
FI990991 1999-04-30

Publications (1)

Publication Number Publication Date
ES2258453T3 true ES2258453T3 (es) 2006-09-01

Family

ID=8554566

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00922683T Expired - Lifetime ES2258453T3 (es) 1999-04-30 2000-04-28 Metodo para identificar un individuo con riesgo de daños neurologicos irreversibles, que comprende las etapas de determinacion cuantitativa de la concentracion de pepsinogeno (i) y vitamina b12.

Country Status (12)

Country Link
EP (1) EP1173764B1 (enExample)
JP (1) JP2002543430A (enExample)
CN (1) CN1353816A (enExample)
AT (1) ATE319088T1 (enExample)
AU (1) AU4299700A (enExample)
DE (1) DE60026285T2 (enExample)
DK (1) DK1173764T3 (enExample)
ES (1) ES2258453T3 (enExample)
FI (1) FI990991L (enExample)
PT (1) PT1173764E (enExample)
RU (1) RU2224258C2 (enExample)
WO (1) WO2000067029A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019L (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
FI20065542A0 (fi) * 2006-09-01 2006-09-01 Biohit Oyj Menetelmä ja näytteenottopakkaus vatsan limakalvon tilan arvioimiseksi
RU2413940C2 (ru) * 2009-02-02 2011-03-10 Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия Способ определения витамина b12 в водных растворах

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97304C (fi) * 1994-11-16 1996-11-25 Locus Genex Oy Menetelmä mahasyövän riskin seulonnaksi

Also Published As

Publication number Publication date
JP2002543430A (ja) 2002-12-17
ATE319088T1 (de) 2006-03-15
FI990991A7 (fi) 2000-10-31
PT1173764E (pt) 2006-06-30
DE60026285T2 (de) 2006-11-09
CN1353816A (zh) 2002-06-12
WO2000067029A1 (en) 2000-11-09
DE60026285D1 (de) 2006-04-27
AU4299700A (en) 2000-11-17
FI990991A0 (fi) 1999-04-30
EP1173764A1 (en) 2002-01-23
RU2224258C2 (ru) 2004-02-20
FI990991L (fi) 2000-10-31
DK1173764T3 (da) 2006-05-08
EP1173764B1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
ES2988827T3 (es) Método in vitro para la detección precoz de un trastorno neurodegenerativo o una depresión utilizando la quinurenina como un marcador
Butani et al. Idiopathic hypercalciuria in children—how valid are the existing diagnostic criteria?
ES2250959T3 (es) Determinacion en un liquido biologico de un peptido parcial de proadrenomedulina de la region media con fines diagnosticos e imnunoensayos para la realizacion de una determinacion de este tipo.
WO2020146497A1 (en) An electrochemiluminescence elisa for ps129-a-synuclein
ES2656082T3 (es) NT-proANP y NT-proBNP para el diagnóstico del accidente cerebrovascular
Pandit et al. Sensing methods for stress biomarker detection in human saliva: a new frontier for wearable electronics and biosensing
KR100394940B1 (ko) 간 질환 진단을 위한 혈중 아사이알로당단백질양의측정방법 및 측정용 킷트
US20200217841A1 (en) In vitro method for the determination of neurodegenerative diseases
ES2258453T3 (es) Metodo para identificar un individuo con riesgo de daños neurologicos irreversibles, que comprende las etapas de determinacion cuantitativa de la concentracion de pepsinogeno (i) y vitamina b12.
US20040229300A1 (en) Zinc-based screening test and kit for early diagnosis of prostate cancer
Wang Concentration of arsenic, selenium, zinc, iron and copper in the urine of blackfoot disease patients at different clinical stages
ES2234299T3 (es) Ensayo para la determinacion de cobalamina.
Symons et al. An evaluation of a fluorescence polarization immunoassay of thyroxin and thyroxin-uptake.
CN101042402A (zh) 用于癌症诊断的自身抗体检测
RU2247389C2 (ru) Способ идентификации индивидуума с риском сосудистого и ракового заболевания
CA2571692A1 (en) Biomarkers of alzheimer's disease
CN101358973A (zh) 基于ZnO纳米棒阵列的肝癌早期诊断试剂盒
Punnonen et al. Evaluation of iron status in anemic patients with rheumatoid arthritis using an automated immunoturbidimetric assay for transferrin receptor
CN102971630A (zh) 非酒精性脂肪性肝炎检测和/或鉴别用标记物、检测和/或鉴别非酒精性脂肪性肝炎的方法及用于它们的试剂盒
ES2284616T3 (es) Ensayo para medir holo-transcobalamina y folato.
Ervens et al. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer
ES2937273T3 (es) Biomarcadores relacionados con la función renal y métodos que implican su uso
Wei et al. Performance Evaluation of CEA Assay on Beckman Coulter UniCel DxI 800
Attia et al. A highly selective and sensitive spectrofluorimetric method for the assessment of 3-nitrotyrosine in serum using (Eu (TTA) 3 Phen) photo probe
Fitzsimons et al. The value of simultaneous urine bilirubin and serum alkaline phosphatase analyses in the diagnosis of intrahepatic metastases of carcinoma